A223250 Stock Overview
Provides clinical research services in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DreamCIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,255.00 |
| 52 Week High | ₩5,390.00 |
| 52 Week Low | ₩2,610.00 |
| Beta | 0.21 |
| 11 Month Change | -33.84% |
| 3 Month Change | -9.58% |
| 1 Year Change | -6.20% |
| 33 Year Change | 13.71% |
| 5 Year Change | n/a |
| Change since IPO | -57.31% |
Recent News & Updates
DreamCIS, Inc.'s (KOSDAQ:223250) Shares Climb 29% But Its Business Is Yet to Catch Up
Oct 21
DreamCIS, Inc.'s (KOSDAQ:223250) 29% Price Boost Is Out Of Tune With Earnings
Jul 11Recent updates
DreamCIS, Inc.'s (KOSDAQ:223250) Shares Climb 29% But Its Business Is Yet to Catch Up
Oct 21DreamCIS, Inc.'s (KOSDAQ:223250) 29% Price Boost Is Out Of Tune With Earnings
Jul 11DreamCIS, Inc.'s (KOSDAQ:223250) Share Price Not Quite Adding Up
Apr 26We Think You Should Be Aware Of Some Concerning Factors In DreamCIS' (KOSDAQ:223250) Earnings
Mar 20Estimating The Intrinsic Value Of DreamCIS, Inc. (KOSDAQ:223250)
Mar 19Shareholder Returns
| A223250 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -0.6% | -7.6% | -0.7% |
| 1Y | -6.2% | 32.0% | -4.1% |
Return vs Industry: A223250 underperformed the KR Life Sciences industry which returned 32% over the past year.
Return vs Market: A223250 underperformed the KR Market which returned -4.1% over the past year.
Price Volatility
| A223250 volatility | |
|---|---|
| A223250 Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A223250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A223250's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 346 | n/a | www.dreamcis.com |
DreamCIS, Inc. provides clinical research services in South Korea. It offers clinical development services; biostatic, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea.
DreamCIS, Inc. Fundamentals Summary
| A223250 fundamental statistics | |
|---|---|
| Market cap | ₩79.97b |
| Earnings (TTM) | ₩3.82b |
| Revenue (TTM) | ₩53.12b |
20.3x
P/E Ratio1.5x
P/S RatioIs A223250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A223250 income statement (TTM) | |
|---|---|
| Revenue | ₩53.12b |
| Cost of Revenue | ₩37.99b |
| Gross Profit | ₩15.13b |
| Other Expenses | ₩11.31b |
| Earnings | ₩3.82b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 160.49 |
| Gross Margin | 28.48% |
| Net Profit Margin | 7.19% |
| Debt/Equity Ratio | 1.4% |
How did A223250 perform over the long term?
See historical performance and comparison